Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 29 | 2022 | 93 | 4.770 |
Why?
|
| Antidepressive Agents | 26 | 2023 | 90 | 3.250 |
Why?
|
| Depressive Disorder | 30 | 2007 | 172 | 2.740 |
Why?
|
| Bipolar Disorder | 14 | 2017 | 102 | 2.070 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 6 | 2023 | 9 | 1.910 |
Why?
|
| Antidepressive Agents, Second-Generation | 13 | 2010 | 28 | 1.290 |
Why?
|
| Psychiatric Status Rating Scales | 26 | 2020 | 296 | 1.110 |
Why?
|
| Ketamine | 2 | 2023 | 23 | 0.940 |
Why?
|
| Antipsychotic Agents | 9 | 2016 | 53 | 0.910 |
Why?
|
| Fluoxetine | 15 | 2009 | 34 | 0.910 |
Why?
|
| Secondary Prevention | 16 | 2020 | 50 | 0.830 |
Why?
|
| Triazoles | 7 | 2003 | 29 | 0.810 |
Why?
|
| Double-Blind Method | 29 | 2020 | 393 | 0.800 |
Why?
|
| Vagus Nerve Stimulation | 2 | 2022 | 8 | 0.730 |
Why?
|
| Tetrahydrofolates | 3 | 2016 | 3 | 0.720 |
Why?
|
| Valproic Acid | 5 | 2008 | 14 | 0.700 |
Why?
|
| Treatment Outcome | 34 | 2022 | 3399 | 0.690 |
Why?
|
| Depression | 7 | 2022 | 412 | 0.690 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2003 | 34 | 0.680 |
Why?
|
| Humans | 78 | 2023 | 25967 | 0.660 |
Why?
|
| Cyclohexanols | 9 | 2010 | 18 | 0.600 |
Why?
|
| Drug Therapy, Combination | 15 | 2019 | 165 | 0.580 |
Why?
|
| Adult | 45 | 2019 | 7662 | 0.570 |
Why?
|
| Male | 56 | 2020 | 14277 | 0.540 |
Why?
|
| Suicidal Ideation | 1 | 2017 | 7 | 0.540 |
Why?
|
| Sexual Dysfunctions, Psychological | 5 | 2005 | 11 | 0.530 |
Why?
|
| Female | 54 | 2020 | 14734 | 0.520 |
Why?
|
| Middle Aged | 36 | 2020 | 8772 | 0.500 |
Why?
|
| Piperazines | 11 | 2015 | 84 | 0.480 |
Why?
|
| Electroconvulsive Therapy | 3 | 2017 | 16 | 0.440 |
Why?
|
| Folic Acid | 2 | 2016 | 21 | 0.400 |
Why?
|
| Anxiety Disorders | 4 | 2002 | 169 | 0.380 |
Why?
|
| Drug Administration Schedule | 15 | 2007 | 160 | 0.360 |
Why?
|
| Acetamides | 1 | 2010 | 3 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 328 | 0.330 |
Why?
|
| Sexual Behavior | 2 | 2002 | 50 | 0.320 |
Why?
|
| Pirenzepine | 3 | 2003 | 5 | 0.300 |
Why?
|
| Adolescent | 13 | 2015 | 2099 | 0.290 |
Why?
|
| Acute Disease | 7 | 2013 | 175 | 0.270 |
Why?
|
| Personality Inventory | 5 | 2012 | 73 | 0.270 |
Why?
|
| Antimanic Agents | 1 | 2006 | 7 | 0.260 |
Why?
|
| Social Adjustment | 2 | 2010 | 23 | 0.250 |
Why?
|
| Aged | 17 | 2016 | 8732 | 0.240 |
Why?
|
| Administration, Intranasal | 2 | 2023 | 28 | 0.240 |
Why?
|
| Sertraline | 5 | 2006 | 24 | 0.230 |
Why?
|
| Chronic Disease | 6 | 2017 | 404 | 0.230 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 1107 | 0.230 |
Why?
|
| Remission Induction | 5 | 2020 | 90 | 0.220 |
Why?
|
| Venlafaxine Hydrochloride | 9 | 2010 | 17 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2017 | 1701 | 0.220 |
Why?
|
| Obsessive-Compulsive Disorder | 4 | 2006 | 15 | 0.220 |
Why?
|
| Placebos | 7 | 2006 | 65 | 0.210 |
Why?
|
| Obesity | 3 | 2015 | 297 | 0.210 |
Why?
|
| Recurrence | 5 | 2016 | 300 | 0.200 |
Why?
|
| Ambulatory Care | 7 | 2008 | 67 | 0.200 |
Why?
|
| Young Adult | 5 | 2016 | 1941 | 0.190 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 1757 | 0.190 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 297 | 0.170 |
Why?
|
| Quality of Life | 5 | 2010 | 605 | 0.170 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 2 | 0.170 |
Why?
|
| Pyrrolidines | 1 | 2020 | 11 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 13 | 0.160 |
Why?
|
| Benzamides | 1 | 2020 | 13 | 0.160 |
Why?
|
| Patient Compliance | 5 | 2007 | 149 | 0.150 |
Why?
|
| Psychotic Disorders | 2 | 2001 | 33 | 0.150 |
Why?
|
| Long-Term Care | 2 | 2016 | 57 | 0.140 |
Why?
|
| Thiazoles | 2 | 2012 | 18 | 0.140 |
Why?
|
| Severity of Illness Index | 6 | 2007 | 868 | 0.140 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2004 | 15 | 0.140 |
Why?
|
| C-Reactive Protein | 2 | 2015 | 97 | 0.140 |
Why?
|
| Phenethylamines | 1 | 2016 | 1 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 273 | 0.130 |
Why?
|
| Pyridines | 1 | 2016 | 30 | 0.130 |
Why?
|
| Comorbidity | 6 | 2015 | 476 | 0.130 |
Why?
|
| Glutamates | 1 | 2015 | 9 | 0.120 |
Why?
|
| Psychometrics | 5 | 2012 | 210 | 0.120 |
Why?
|
| Registries | 1 | 2017 | 192 | 0.120 |
Why?
|
| Serotonin | 2 | 1997 | 23 | 0.120 |
Why?
|
| Dizziness | 4 | 2007 | 17 | 0.120 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2007 | 4 | 0.120 |
Why?
|
| Hypericum | 2 | 2005 | 3 | 0.120 |
Why?
|
| Paroxetine | 4 | 2007 | 14 | 0.120 |
Why?
|
| Phytotherapy | 2 | 2005 | 11 | 0.120 |
Why?
|
| Sulfides | 1 | 2015 | 10 | 0.120 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 38 | 0.110 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2014 | 1 | 0.110 |
Why?
|
| Aldehydes | 1 | 2014 | 2 | 0.110 |
Why?
|
| S-Adenosylmethionine | 1 | 2014 | 5 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2019 | 104 | 0.110 |
Why?
|
| Vagus Nerve | 2 | 2022 | 14 | 0.110 |
Why?
|
| Inflammation | 1 | 2015 | 267 | 0.110 |
Why?
|
| Nausea | 3 | 1999 | 24 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 337 | 0.110 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2000 | 104 | 0.100 |
Why?
|
| Anticonvulsants | 2 | 2003 | 54 | 0.100 |
Why?
|
| Hypertension | 2 | 2007 | 181 | 0.100 |
Why?
|
| Tranylcypromine | 1 | 1991 | 2 | 0.090 |
Why?
|
| Prevalence | 1 | 2013 | 433 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2005 | 649 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 40 | 0.090 |
Why?
|
| Headache | 3 | 2007 | 37 | 0.090 |
Why?
|
| Patient Education as Topic | 3 | 2003 | 128 | 0.090 |
Why?
|
| Orgasm | 1 | 1991 | 9 | 0.090 |
Why?
|
| Fever | 1 | 1991 | 34 | 0.090 |
Why?
|
| Attitude to Health | 2 | 2002 | 95 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 5 | 0.080 |
Why?
|
| Duloxetine Hydrochloride | 2 | 2015 | 9 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 190 | 0.080 |
Why?
|
| Choice Behavior | 1 | 2010 | 45 | 0.080 |
Why?
|
| Electroencephalography | 1 | 2010 | 80 | 0.080 |
Why?
|
| Tachyphylaxis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Benzodiazepines | 3 | 2003 | 45 | 0.070 |
Why?
|
| Delayed-Action Preparations | 4 | 2010 | 28 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2015 | 957 | 0.070 |
Why?
|
| Sleep Stages | 2 | 1999 | 19 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 9 | 0.070 |
Why?
|
| 1-Naphthylamine | 2 | 1997 | 4 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 29 | 0.070 |
Why?
|
| Half-Life | 2 | 1997 | 11 | 0.070 |
Why?
|
| Serotonin Antagonists | 2 | 2001 | 8 | 0.070 |
Why?
|
| Syndrome | 2 | 1997 | 73 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 41 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2010 | 252 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2007 | 66 | 0.060 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2004 | 6 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 89 | 0.060 |
Why?
|
| Weight Gain | 3 | 2001 | 59 | 0.060 |
Why?
|
| Electric Stimulation Therapy | 1 | 2005 | 39 | 0.060 |
Why?
|
| Sex Factors | 2 | 2005 | 454 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2007 | 3358 | 0.060 |
Why?
|
| Thiophenes | 1 | 2004 | 10 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2003 | 38 | 0.050 |
Why?
|
| Morpholines | 1 | 2003 | 14 | 0.050 |
Why?
|
| Health Status | 3 | 2003 | 214 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2002 | 6 | 0.050 |
Why?
|
| Body Weight | 2 | 2002 | 132 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2003 | 37 | 0.050 |
Why?
|
| Biomarkers | 2 | 2015 | 544 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2002 | 43 | 0.050 |
Why?
|
| Drug Interactions | 2 | 1991 | 35 | 0.050 |
Why?
|
| Mianserin | 1 | 2001 | 8 | 0.050 |
Why?
|
| Buspirone | 1 | 2001 | 4 | 0.040 |
Why?
|
| Bupropion | 1 | 2001 | 6 | 0.040 |
Why?
|
| Sildenafil Citrate | 1 | 2001 | 10 | 0.040 |
Why?
|
| Sulfones | 1 | 2001 | 20 | 0.040 |
Why?
|
| Psychomotor Agitation | 1 | 2001 | 12 | 0.040 |
Why?
|
| Sexuality | 1 | 2001 | 14 | 0.040 |
Why?
|
| Telephone | 1 | 2000 | 26 | 0.040 |
Why?
|
| Central Nervous System Stimulants | 1 | 2001 | 39 | 0.040 |
Why?
|
| Self Disclosure | 1 | 2000 | 6 | 0.040 |
Why?
|
| Purines | 1 | 2001 | 41 | 0.040 |
Why?
|
| Asthenia | 1 | 2000 | 1 | 0.040 |
Why?
|
| Desipramine | 1 | 2000 | 3 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 252 | 0.040 |
Why?
|
| Feeding and Eating Disorders | 1 | 2000 | 10 | 0.040 |
Why?
|
| Nasal Sprays | 1 | 2019 | 1 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2000 | 86 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 473 | 0.040 |
Why?
|
| Anxiety | 1 | 1999 | 146 | 0.040 |
Why?
|
| Drug Synergism | 2 | 1995 | 39 | 0.040 |
Why?
|
| Prognosis | 1 | 2000 | 784 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1997 | 2 | 0.030 |
Why?
|
| MEDLINE | 1 | 1997 | 5 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 1997 | 10 | 0.030 |
Why?
|
| Time Factors | 3 | 2010 | 1391 | 0.030 |
Why?
|
| Abbreviations as Topic | 1 | 1997 | 1 | 0.030 |
Why?
|
| Paresthesia | 1 | 1997 | 2 | 0.030 |
Why?
|
| Receptors, Serotonin | 1 | 1997 | 12 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1997 | 11 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1997 | 15 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1997 | 30 | 0.030 |
Why?
|
| Life Change Events | 1 | 1997 | 37 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1997 | 30 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 31 | 0.030 |
Why?
|
| Quetiapine Fumarate | 1 | 2016 | 3 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1997 | 99 | 0.030 |
Why?
|
| Triazines | 1 | 2016 | 11 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1997 | 210 | 0.030 |
Why?
|
| Imipramine | 1 | 1996 | 10 | 0.030 |
Why?
|
| Family Practice | 1 | 1996 | 14 | 0.030 |
Why?
|
| Community Mental Health Services | 1 | 1996 | 15 | 0.030 |
Why?
|
| Primary Health Care | 1 | 1997 | 78 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2006 | 46 | 0.030 |
Why?
|
| Adiponectin | 1 | 2015 | 10 | 0.030 |
Why?
|
| Infant | 1 | 1997 | 495 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 19 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 1995 | 6 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1997 | 140 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 1997 | 545 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 74 | 0.030 |
Why?
|
| Plant Extracts | 2 | 2005 | 15 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1995 | 32 | 0.030 |
Why?
|
| Affect | 1 | 1995 | 59 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 181 | 0.030 |
Why?
|
| Phobic Disorders | 1 | 1995 | 66 | 0.030 |
Why?
|
| Incidence | 1 | 1997 | 729 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1995 | 134 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 1995 | 92 | 0.030 |
Why?
|
| Carbamazepine | 1 | 1993 | 6 | 0.030 |
Why?
|
| Lithium | 1 | 1993 | 19 | 0.030 |
Why?
|
| Child | 1 | 1997 | 1217 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 339 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 82 | 0.020 |
Why?
|
| Amitriptyline | 1 | 1991 | 3 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 1991 | 5 | 0.020 |
Why?
|
| Pemoline | 1 | 1991 | 1 | 0.020 |
Why?
|
| Dextroamphetamine | 1 | 1991 | 2 | 0.020 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1991 | 16 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 1150 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 1991 | 24 | 0.020 |
Why?
|
| Risk Factors | 1 | 1997 | 2237 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1990 | 5 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 100 | 0.020 |
Why?
|
| Hospitalization | 1 | 1991 | 301 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 174 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2007 | 19 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2007 | 24 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 28 | 0.020 |
Why?
|
| Outpatients | 1 | 2007 | 56 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 137 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1333 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2005 | 22 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2005 | 25 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 181 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2007 | 227 | 0.010 |
Why?
|
| United States | 1 | 2010 | 1989 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 2003 | 3 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 571 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 64 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 6 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 258 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 65 | 0.010 |
Why?
|
| Priapism | 1 | 2002 | 10 | 0.010 |
Why?
|
| Suicide | 1 | 2002 | 12 | 0.010 |
Why?
|
| Seizures | 1 | 2002 | 68 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2001 | 24 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2001 | 8 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2001 | 13 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2001 | 63 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2001 | 50 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 152 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 311 | 0.010 |
Why?
|
| Appetite | 1 | 1999 | 4 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 757 | 0.010 |
Why?
|
| Weight Loss | 1 | 1999 | 122 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1999 | 449 | 0.010 |
Why?
|